Medicinal study gave international prize
Treatment with a new blood platelet inhibiting medicine against heart attacks and unstable angina pectoris could mean that fewer patients suffer relapses and die. Moreover, the costs of health care are reduced. This is shown in an LiU study that was recently awarded a prize at the American Heart Association’s annual congress.
The PLATO study is a health economics evaluation conducted by a research group at CMT, the Center for Medical Technology Assessment, under the leadership of Magnus Janzon, MD at LiU and department director at the Cardiological Clinic.
“Our work was ranked highest among all contributions in the field of heart disease – biology and clinical science. It was also noticed quite a bit during the meeting,” Janzon says.
11,000 contributions in total competed in seven fields.
Ticareglor, a medicine from Astra Zeneca, works by inhibiting activity in blood platelets, which contributes to blood clot formation. It has passed all the phases of clinical testing and it now remains to be shown that it is also a treatment that is defensible from a health economic perspective before it can be released onto the market. The task fell a few years ago to the CMT group, which since then has been reviewing the outcomes among 18,000 patients in 44 countries.
“We have shown that Ticareglor is a better treatment than the medicine we have today. Fewer patients suffer relapses and die, and this also results in reduced health care costs,” Janzon says.
The presentation at the congress was the first release of the health economic study to the public. A scientific article will soon be ready for publication.
Last updated: 2011-03-01